| scholarly article | Q13442814 |
| P2093 | author name string | A K Nowak | |
| R A Lake | |||
| B W S Robinson | |||
| H J Steer | |||
| P2860 | cites work | Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells | Q78409834 |
| Regulatory CD4+ T cells are crucial for preventing CD8+ T cell-mediated autoimmunity | Q81305952 | ||
| Immunotherapy and chemotherapy--a practical partnership | Q81703535 | ||
| HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine | Q83133039 | ||
| Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire | Q84075121 | ||
| Antigen presentation and T cell stimulation by dendritic cells | Q22255632 | ||
| The response of autologous T cells to a human melanoma is dominated by mutated neoantigens | Q24535034 | ||
| CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. | Q24540429 | ||
| T cell homeostatic proliferation elicits effective antitumor autoimmunity | Q24553060 | ||
| A small-cell lung cancer genome with complex signatures of tobacco exposure | Q24600510 | ||
| A comprehensive catalogue of somatic mutations from a human cancer genome | Q24628532 | ||
| Secondary replicative function of CD8+ T cells that had developed an effector phenotype | Q24642499 | ||
| T helper 17 cells promote cytotoxic T cell activation in tumor immunity | Q24646584 | ||
| Characterizing the cancer genome in lung adenocarcinoma | Q24649926 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation | Q24677534 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity | Q28138211 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| The danger model: a renewed sense of self | Q28214633 | ||
| PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells | Q28243975 | ||
| Calreticulin exposure dictates the immunogenicity of cancer cell death | Q28280438 | ||
| Regulatory T cell lineage specification by the forkhead transcription factor foxp3 | Q28510328 | ||
| Phagosomes are competent organelles for antigen cross-presentation | Q28591811 | ||
| Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors | Q29615665 | ||
| Molecular identification of a danger signal that alerts the immune system to dying cells | Q29619497 | ||
| Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy | Q29619961 | ||
| Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control | Q30444800 | ||
| In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes | Q31583375 | ||
| Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells | Q31813068 | ||
| Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth | Q33502208 | ||
| Cross-presentation of tumour antigens: evaluation of threshold, duration, distribution and regulation. | Q33778847 | ||
| Phosphatidylserine regulates the maturation of human dendritic cells. | Q45025098 | ||
| Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide | Q45182740 | ||
| Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma | Q45287769 | ||
| CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. | Q46028085 | ||
| Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients | Q46093084 | ||
| Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy | Q46217068 | ||
| Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation | Q46674193 | ||
| Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses | Q46725768 | ||
| Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with "division arrest anergy". | Q47819013 | ||
| Help for cytotoxic-T-cell responses is mediated by CD40 signalling | Q47982749 | ||
| Modifications of CD8+ T Cell Function during In Vivo Memory or Tolerance Induction | Q47992203 | ||
| Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells | Q51919478 | ||
| The critical role of Th1-dominant immunity in tumor immunology. | Q52025034 | ||
| Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo | Q53573167 | ||
| Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. | Q53851520 | ||
| Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients | Q57220173 | ||
| Cell-Associated Ovalbumin Is Cross-Presented Much More Efficiently than Soluble Ovalbumin In Vivo | Q57227930 | ||
| Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer | Q57254166 | ||
| Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells | Q57275942 | ||
| NOX2 Controls Phagosomal pH to Regulate Antigen Processing during Crosspresentation by Dendritic Cells | Q58007061 | ||
| Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL | Q61466188 | ||
| CD4 + CD25 + Cells Controlling a Pathogenic CD4 Response Inhibit Cytokine Differentiation, CXCR-3 Expression, and Tissue Invasion | Q63346582 | ||
| Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer | Q64378051 | ||
| The risk of autoimmunity associated with tumor immunotherapy | Q74434052 | ||
| Endocytosis mechanisms and the cell biology of antigen presentation | Q37076774 | ||
| Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy | Q37087603 | ||
| Multiple roles for CD4+ T cells in anti-tumor immune responses | Q37118150 | ||
| Human regulatory T cells and autoimmunity | Q37131908 | ||
| Inhibitory B7-family molecules in the tumour microenvironment | Q37171804 | ||
| Specificity in cancer immunotherapy | Q37236636 | ||
| The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation | Q37322936 | ||
| Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. | Q37418499 | ||
| Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? | Q37492248 | ||
| Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells | Q37600964 | ||
| Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia | Q39296306 | ||
| Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses | Q39758426 | ||
| Immunogenic death of colon cancer cells treated with oxaliplatin | Q39780621 | ||
| Chemotherapy induces ATP release from tumor cells | Q39783670 | ||
| Cutting edge: Necrosis activates the NLRP3 inflammasome | Q39825783 | ||
| Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-ex | Q39880448 | ||
| Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. | Q39934421 | ||
| The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death | Q39984426 | ||
| Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors | Q40022319 | ||
| Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer | Q40026321 | ||
| Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy | Q40222466 | ||
| Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference | Q40224792 | ||
| Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity | Q40286194 | ||
| Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors | Q40352199 | ||
| Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity | Q40372686 | ||
| Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. | Q40377919 | ||
| Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation | Q40495409 | ||
| CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative | Q40591372 | ||
| IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. | Q40618350 | ||
| Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs | Q41057373 | ||
| How many mutations in a cancer? | Q41834410 | ||
| A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion | Q42674919 | ||
| Immunology. Ex uno plura | Q42732716 | ||
| Delayed clearance of apoptotic lymphoma cells allows cross-presentation of intracellular antigens by mature dendritic cells. | Q42811987 | ||
| Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor | Q43102307 | ||
| Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy | Q43705031 | ||
| Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells | Q44432115 | ||
| Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses | Q33977826 | ||
| Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity | Q34046869 | ||
| Death by design: apoptosis, necrosis and autophagy | Q34365753 | ||
| Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells | Q34397184 | ||
| Regulatory T cells in cancer | Q34550248 | ||
| CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit | Q34601772 | ||
| Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. | Q34623431 | ||
| Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments | Q34983123 | ||
| T helper lymphocytes rescue CTL from activation-induced cell death | Q35073666 | ||
| Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy | Q35540109 | ||
| Danger signals: a time and space continuum. | Q35791962 | ||
| Pathways of apoptotic and non-apoptotic death in tumour cells | Q35852309 | ||
| Innate immune recognition of nucleic acids | Q35868815 | ||
| CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses | Q35978636 | ||
| Role of transforming growth factor Beta in human cancer | Q36073421 | ||
| Mechanisms of suppression by suppressor T cells | Q36078047 | ||
| The controversial abscopal effect | Q36143531 | ||
| Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. | Q36228158 | ||
| CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function | Q36369713 | ||
| Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. | Q36372880 | ||
| Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells | Q36399149 | ||
| Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation | Q36403539 | ||
| Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways | Q36404658 | ||
| Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy | Q36470726 | ||
| Immune suppression in the tumor microenvironment | Q36478177 | ||
| Combined chemoimmunotherapy of solid tumours: improving vaccines? | Q36605604 | ||
| Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors | Q36893068 | ||
| Structure and function: heat shock proteins and adaptive immunity. | Q36901412 | ||
| TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells | Q36924688 | ||
| Cytotoxic T-lymphocyte-associated antigen-4. | Q36944367 | ||
| Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference | Q36949870 | ||
| Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors | Q36965879 | ||
| The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy | Q36990578 | ||
| Immunological aspects of cancer chemotherapy | Q37039588 | ||
| P433 | issue | 48 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6301-6313 | |
| P577 | publication date | 2010-09-20 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Harnessing the immune response to treat cancer | |
| P478 | volume | 29 |
| Q52731753 | A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells. |
| Q33571981 | A mathematical model for pancreatic cancer growth and treatments |
| Q56898024 | An immune-active tumor microenvironment favors clinical response to ipilimumab |
| Q36085104 | Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment |
| Q30637447 | AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells |
| Q38869740 | Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis |
| Q38734506 | Antitumor Effects of Orally and Intraperitoneally Administered Chitosan Oligosaccharides (COSs) on S180-Bearing/Residual Mouse |
| Q36541076 | C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation |
| Q57462232 | CD8 T-Cell Density Imaging with Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols |
| Q38223355 | Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment |
| Q37950700 | Chemokines in tumor development and progression. |
| Q34226903 | Chemotherapy enhances cross-presentation of nuclear tumor antigens |
| Q33889105 | Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity |
| Q36395752 | CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery |
| Q37588227 | Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma |
| Q36177023 | Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors. |
| Q39534587 | Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells |
| Q38975033 | Evaluation of anti-cancer and immunomodulatory effects of carnosol in a Balb/c WEHI-164 fibrosarcoma model. |
| Q39232427 | Examining T Cells at Vaccine Sites of Tumor-bearing Hosts Provides Insights to Dysfunctional T-Cell Immunity |
| Q44503506 | HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression |
| Q37295663 | IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer |
| Q43916071 | Increased tumor-infiltrating CD8+Foxp3+ T lymphocytes are associated with tumor progression in human gastric cancer |
| Q35955224 | Increasing vaccine potency through exosome antigen targeting |
| Q40268002 | Inducible TAP1 Negatively Regulates the Antiviral Innate Immune Response by Targeting the TAK1 Complex. |
| Q36038385 | Infiltrating CTLs are bothered by HLA-E on tumors |
| Q37997202 | Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy |
| Q30360210 | Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. |
| Q38096411 | Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors |
| Q58122935 | Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer |
| Q28081582 | T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview |
| Q37222202 | TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models |
| Q27022348 | Targeting regulatory T cells in cancer |
| Q38847321 | The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer |
| Q51065862 | Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers |
| Q42109061 | Tumor Necrosis Factor (TNF) and Chemokines in Colitis-Associated Cancer |
| Q64979554 | Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ2 mediated pathway. |
| Q39499046 | pDNA-lipoplexes engrafted with flagellin-related peptide induce potent immunity and anti-tumour effects |
Search more.